CAMPBELL, CA --(Marketwired - October 31, 2017) - VIVUS, Inc. (
To listen via webcast, please visit http://ir.vivus.com/ , or by clicking here .
To listen via phone, please use the dial in information provided below.
Dial in Details: Toll-Free: (877) 359-2916 International: (224) 357-2386 Passcode: 7997677
A webcast replay will be available on the VIVUS website for 30 days.
About VIVUS VIVUS is a biopharmaceutical company developing and commercializing innovative, next-generation therapies to address unmet medical needs in human health. For more information about the company, please visit www.vivus.com .
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," "intend," "likely," "may," "plan," "potential," "predict," "opportunity" and "should," among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. VIVUS does not undertake an obligation to update or revise any forward-looking statements. Investors should read the risk factors set forth in VIVUS' Form 10-K for the year ended December 31, 2016 as filed on March 8, 2017, and as amended by the Form 10-K/A filed on April 26, 2017, and periodic reports filed with the Securities and Exchange Commission.
CONTACT: VIVUS, Inc. Mark Oki Chief Financial Officer oki@vivus.com 650-934-5200 Investor Relations Lazar Partners Matthew Ventimiglia mventimiglia@lazarpartners.com 212-599-1265